1. Home
  2. COCP vs ROMA Comparison

COCP vs ROMA Comparison

Compare COCP & ROMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • COCP
  • ROMA
  • Stock Information
  • Founded
  • COCP 2006
  • ROMA 2018
  • Country
  • COCP United States
  • ROMA Hong Kong
  • Employees
  • COCP N/A
  • ROMA N/A
  • Industry
  • COCP Biotechnology: Pharmaceutical Preparations
  • ROMA Savings Institutions
  • Sector
  • COCP Health Care
  • ROMA Finance
  • Exchange
  • COCP Nasdaq
  • ROMA Nasdaq
  • Market Cap
  • COCP 15.3M
  • ROMA 18.1M
  • IPO Year
  • COCP N/A
  • ROMA 2024
  • Fundamental
  • Price
  • COCP $1.52
  • ROMA $2.10
  • Analyst Decision
  • COCP Strong Buy
  • ROMA
  • Analyst Count
  • COCP 1
  • ROMA 0
  • Target Price
  • COCP $7.00
  • ROMA N/A
  • AVG Volume (30 Days)
  • COCP 12.6K
  • ROMA 113.5K
  • Earning Date
  • COCP 05-20-2025
  • ROMA 12-16-2024
  • Dividend Yield
  • COCP N/A
  • ROMA N/A
  • EPS Growth
  • COCP N/A
  • ROMA N/A
  • EPS
  • COCP N/A
  • ROMA N/A
  • Revenue
  • COCP N/A
  • ROMA $1,029,120.00
  • Revenue This Year
  • COCP N/A
  • ROMA N/A
  • Revenue Next Year
  • COCP N/A
  • ROMA N/A
  • P/E Ratio
  • COCP N/A
  • ROMA N/A
  • Revenue Growth
  • COCP N/A
  • ROMA N/A
  • 52 Week Low
  • COCP $1.12
  • ROMA $0.40
  • 52 Week High
  • COCP $3.26
  • ROMA $2.05
  • Technical
  • Relative Strength Index (RSI)
  • COCP 51.20
  • ROMA 95.94
  • Support Level
  • COCP $1.36
  • ROMA $1.61
  • Resistance Level
  • COCP $1.74
  • ROMA $2.58
  • Average True Range (ATR)
  • COCP 0.18
  • ROMA 0.20
  • MACD
  • COCP 0.01
  • ROMA 0.09
  • Stochastic Oscillator
  • COCP 50.00
  • ROMA 68.77

About COCP Cocrystal Pharma Inc.

Cocrystal Pharma Inc is a biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of influenza viruses, hepatitis C viruses, and noroviruses. It employs structure-based technologies and Nobel Prize-winning expertise to create first- and-in-class antiviral drugs. It is developing CC-31244, an investigational, oral, broad-spectrum replication inhibitor called a non-nucleoside inhibitor (NNI).

About ROMA Roma Green Finance Limited

Roma Green Finance Ltd is principally engaged in the provision of ESG, corporate governance and risk management as well as sustainability and climate change-related advisory services. The company works closely with its clients to help them understand, identify, manage and overcome various business matters arising from such factors related to ESG, sustainability and climate change. it provides tailored-made sustainability solutions to meet the client's specific needs. Its mission is to provide its clients with a one-stop destination for high-quality and holistic sustainability and climate change-related consulting services to support a more sustainable, balanced and inclusive future for its clients' organizations and the world.

Share on Social Networks: